Dr. John Cush RheumNow
3 years 10 months ago
Our newest RheumNow reporter, Dr. Michael Putman , will be covering SLE and Vasculitis at #ACR22 this year.
“Looking forward to seeing all my friends and colleagues in person!”-Dr. Putnam
Follow him @EBRheum for real-time coverage! https://t.co/DpFa0zwzPX
New research being presented this week at ACR Convergence 2022, demonstrated that polyarticular juvenile idiopathic arthritis patients were more likely to achieve clinical remission with a combination of conventional and biologic DMARDs compared with other consensus treatment plans by the Childhood Arthritis and Rheumatology Research Alliance (CARRA).
Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic musculoskeletal disease which can be managed with both pharmacological and non-pharmacological options. The joint ASAS-EULAR recommendations for axSpA were first developed in 2006, and last updated in 2016. The current update reflects newly available evidence since the last version.
Dr. John Cush RheumNow
3 years 10 months ago
QD Clinic - 1st Line Anakinra
New-onset systemic JIA - how will you treat? #ACR22
https://t.co/cxG6ZcBXUv https://t.co/YCXD4z9BQ7
Dr. John Cush RheumNow
3 years 10 months ago
Video Telehealth Willingness Increased During Pandemic
Americans’ willingness to use video telehealth has increased since the beginning of the pandemic, rising most sharply among Black Americans and people with less education, according to a new study.
https://t.co/oi3C2A7yJt https://t.co/H8AhiXeU3r
Dr. John Cush RheumNow
3 years 10 months ago
#ACR22 Will Present New Recommendations for Integrative Approach to RA Treatment
https://t.co/FI5k6LIKrO https://t.co/I0F1wJNBDc
Dr. John Cush RheumNow
3 years 10 months ago
Plaquenil (HCQ) reduces #SLE mortality. Metanalysis (21 studies, 26,037 pts). Pooled findings - HCQ significantly reduced SLE mortality (HR 0.46); HCQ also reduced mortality in SLE pts w/ renal (HR=0.43), & cardiopulmonary dz (HR=0.37) https://t.co/fsHaN8wR17 https://t.co/MW8cvavzBC
Dr. John Cush RheumNow
3 years 10 months ago
Opportunistic Infections with JAK inhibitors in RA
Winthrop and colleagues have reviewed the occurrence of OIs associated with the use of JAK inhibitors in patients with RA, showing that Herpez zoster (HZ) was the most common OI reported.
https://t.co/CtFcnHiWKS https://t.co/qKU51vLxaP
Dr. John Cush RheumNow
3 years 10 months ago
We're excited to have Dr. Aurelia Najm back as an #ACR22 RheumNow reporter!
"I look forward to learning about developments in the field and finally meet with colleagues and collaborators from all over the world. "
-Dr. Najm
Follow @AurelieRheumo for real time #ACR22 coverage! https://t.co/o6Mhobt2BR
Dr. John Cush RheumNow
3 years 10 months ago
Dr. Robert Chao is back as a RheumNow reporter for a third year.
"I’m looking forward to the exciting hybrid format of both in person and virtual meeting this year! "
Follow @doctorRBC for real-time #ACR22 coverage! https://t.co/j6FNra7aZq
Dr. John Cush RheumNow
3 years 10 months ago
Join Dr. Jack Cush and Dr. Arthur Kavanaugh as they discuss, dissect and deliberate about data presented at the #ACR22 meeting in Philadelphia.
https://t.co/STvWZMS7xS https://t.co/oQt3ZMyjEN
Dr. John Cush RheumNow
3 years 10 months ago
QD Clinic - Seropositive Arthralgia (abstract #1604)
42 yr old woman with +RF and Arthralgias only. How to treat?
https://t.co/MgPFHa0CAd https://t.co/Aqlrc6rOSt
Dr. John Cush RheumNow
3 years 10 months ago
2022 EULAR Recommendations for Screening and Prophylaxis of Chronic and Opportunistic Infections
A EULAR Task force has developed recommendations for screening and prophylaxis of chronic and opportunistic infections in patients with AIIRD.
https://t.co/VrdNggfMfG https://t.co/WARs0YJLZs
